Home/RevaTis/Didier Serteyn
DS

Didier Serteyn

CEO

RevaTis

RevaTis Pipeline

DrugIndicationPhase
Autologous MSC Therapy for Veterinary UseMusculoskeletal disorders (e.g., osteoarthritis, tendonitis) in horses and companion animalsPre-clinical
Personalized Stem Cell Supply for ResearchResearch tools for biobanking, organ-on-a-chip, 3D bioprintingN/A (Service)